



REMARKS

The Brief Description of the Drawings has been amended to include sequence identification number for the sequence, shown in Figure 2.

Attached hereto is a marked-up version showing the changes made to the specification by the current amendment. The attached page is entitled: "**Version with markings to show changes made**".

The undersigned hereby states that the computer readable form copy (CRF copy) of the substitute Sequence Listing and the paper copy of the substitute Sequence Listing, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the substitute Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 under Order No. 251002009400. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: May 23, 2002

By: U. Britva
Irina E. Britva
Registration No. 50,498

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5175
Facsimile: (858) 720-5125

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

The paragraph, beginning at page 6, line 1, has been amended as follows:

Fig. 2 shows the structure in the vicinity of a multi-cloning site of the plasmid vector (SEQ ID NO:1), pGFPsfII, for expression of fusion proteins with GFP.

FIG.2

